Topics

Cambrex signs $252m agreement to acquire Avista Pharma

19:00 EST 20 Nov 2018 | Pharmaceutical Technology

Generic active pharmaceutical ingredients (APIs) manufacturer Cambrex has signed a $252m definitive agreement to purchase Avista Pharma Solutions (Avista). A...
Read More...

The post Cambrex signs $252m agreement to acquire Avista Pharma appeared first on Pharmaceutical Technology.

Original Article: Cambrex signs $252m agreement to acquire Avista Pharma

NEXT ARTICLE

More From BioPortfolio on "Cambrex signs $252m agreement to acquire Avista Pharma"

Quick Search

Relevant Topics

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...